Lisa Shives, MD
Sleep Medicine · San Diego, CANPI 1740322825
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,369,103 of the $1,372,111 with a category attached, or 99.8%. SNAP Diagnostics LLC accounts for 98.8% of it on its own, with 3 other manufacturers making up the rest. Among sleep medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 25 payments — averaging $54,884 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SNAP Diagnostics LLC$1.4M
- Jazz Pharmaceuticals Inc.$15K
- Harmony Biosciences LLC$2K
- Avadel CNS Pharmaceuticals, LLC$150
What the payments were for
- Consulting fees$1,3500%
- Speaking & faculty fees$1,369,103100%
- Travel & lodging$1,2060%
- Food & beverage$3820%
- Education$700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SNAP Diagnostics LLC | 7 | $1,355,823 |
| Jazz Pharmaceuticals Inc. | 13 | $14,574 |
| Harmony Biosciences LLC | 4 | $1,564 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $150 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SNAP Diagnostics study$1,005,816
- XYWAV$14,282
- Wakix$1,471
- LUMRYZ$150
How this compares
$1,372,111 in reported general payments places this provider in the 95th percentile of 200 sleep medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,957 |
| Dextroamphetamine Sulfate | 13 | $2,385 |
| Eszopiclone | 35 | $640 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 22 | $487 |
| Modafinil | 11 | $349 |
| Zolpidem Tartrate | 13 | $46 |
Paid to pharmacies, not to this prescriber.
Other sleep medicine in San Diego
- Atul MalhotraSan Diego$771K
- Pegah MashayekhiSan Diego$25K
- Robert OwensSan Diego$5K
- Haramandeep SinghSan Ramon$1.1M
- Logan SchneiderStanford$506K
- Tony MasriLos Gatos$327K
- Sam KashaniSanta Monica$221K
- Emmanuel MignotStanford$135K
- Jerome HesterPalo Alto$74K
- Mark BuchfuhrerDowney$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.